Boeing secures $883 million Army contract for cargo support services
Pulmonx Corp (NASDAQ:LUNG) shares tumbled to a 52-week low of $3.17, reflecting a stark downturn in investor sentiment. The company maintains strong liquidity with a current ratio of 4.97 and more cash than debt on its balance sheet, according to InvestingPro data. Over the past year, the company has witnessed a significant decline, with the stock price eroding by -64.47%. This substantial drop underscores the challenges faced by Pulmonx in a competitive and ever-evolving medical devices market. Despite the challenges, the company achieved revenue growth of 19.84% in the last twelve months. Investors are closely monitoring the company’s performance and strategic initiatives as it navigates through these headwinds in hopes of a turnaround. InvestingPro analysis suggests the stock is currently undervalued, with additional insights available in the comprehensive Pro Research Report.
In other recent news, Pulmonx Corp reported its first-quarter 2025 earnings, revealing a narrower-than-expected loss per share of $0.36, which was better than the forecasted loss of $0.39. However, the company’s revenue of $22.5 million slightly missed the $22.03 million expectation. Despite this, Pulmonx reaffirmed its full-year revenue guidance of $96-98 million, indicating confidence in future growth. Stifel analysts maintained a Buy rating for Pulmonx with a $16.00 price target, citing potential U.S. sales growth in the latter half of 2025 driven by strategic initiatives. Canaccord Genuity also kept a Buy rating, although they lowered their price target to $15.00 due to broader market valuation trends. They expressed optimism in Pulmonx’s long-term growth prospects, highlighting the company’s commitment to maintaining a high growth rate. Pulmonx’s management is focusing on expanding its international footprint, particularly in China, which contributed significantly to the company’s 20% year-over-year revenue growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.